Although MYCN gene amplification and/or N-Myc oncoprotein overexpression is found in ~ 40% NEPC [5] and up to 20% CRPC without neuroendocrine phenotype [13], they are also found in ~ 5% PCA [5, 28], suggesting that these amplification events can arise early before hormonal therapy. The gene discussed is MYCN; the disease is posterior cortical atrophy.